Amygdala Neurosciences Inc., a biopharma company developing drug candidates for addiction disorders, has entered into an agreement with Gilead Sciences to acquire GS-6637, a highly selective ALDH2 inhibitor with the potential to treat behavior and substance addictions based on a mechanism of action that prevents dopamine surges and associated craving without changes to basal dopamine.   “Completion of this transaction launches Amygdala Neurosciences with a Phase-2 ready asset that we b...